Last reviewed · How we verify
RPH-002
RPH-002 is a small molecule that targets the [insert target here, if known].
RPH-002 is a small molecule that targets the [insert target here, if known]. Used for Phase 3 for [insert indication here, if known].
At a glance
| Generic name | RPH-002 |
|---|---|
| Also known as | Arcetux®, L01002, cetuximab |
| Sponsor | R-Pharm |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, I do not have enough information to provide a deeper explanation of the mechanism.
Approved indications
- Phase 3 for [insert indication here, if known]
Common side effects
Key clinical trials
- A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPH-002 CI brief — competitive landscape report
- RPH-002 updates RSS · CI watch RSS
- R-Pharm portfolio CI